Actively Recruiting
Phase I Study of JYP0322 in ROS1 Fusion-Positive Solid Tumors
Led by Guangzhou JOYO Pharma Co., Ltd · Updated on 2025-07-14
101
Participants Needed
1
Research Sites
295 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
An open, non-randomized, multicenter, single-arm dose-escalation design, phase 1 trial to study the safety, tolerability, pharmacokinetics and efficacy of JYP0322 in patients with ROS1+ locally advanced/metastatic solid tumors .
CONDITIONS
Official Title
Phase I Study of JYP0322 in ROS1 Fusion-Positive Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult patients age 18 years or older
- Diagnosed with locally advanced or metastatic solid tumors with a ROS1 molecular fusion
- Measurable disease according to RECIST version 1.1
- Life expectancy of at least 3 months
- Other protocol specified criteria
You will not qualify if you...
- Currently participating in another therapeutic clinical trial
- Gastrointestinal diseases affecting drug absorption, such as Crohn's disease, ulcerative colitis, or short gut syndrome
- History of severe allergies or hypersensitivity to any ingredient of the study drug
- Known active infections including bacterial, viral, or HIV
- Other protocol specified criteria
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Sun Yat-Sen University Cancer Center
Guangzhou, Guangdong, China, 510060
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
7
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here